Literature DB >> 24877187

Improving adherence to oral cancer therapy in clinical practice.

Debbie A McCue, Lisa K Lohr, Amy M Pick.   

Abstract

Adherence to oral chemotherapy regimens maximizes their effectiveness and minimizes any potential toxicities. Factors specifically related to the treatment, patient, and health care provider may influence medication adherence. Treatment-related factors include the complexity of the regimen, the cost of therapy, the possibility of side effects, and the delay in treatment benefits. Meanwhile, patients may not have an adequate support system or an understanding of the need for the medication, and providers may not fully succeed in communicating the importance of adherence and the types of side effects that may occur. Nonadherence may lead to an increased risk of toxicity, decreased effectiveness, and increased utilization of health care resources. Although various methods for measuring adherence are available, self-reporting is the most widely used. Studies describing adherence in a broad range of cancers are reviewed. Treatment of chronic myeloid leukemia has been revolutionized by the development of oral tyrosine kinase inhibitors that are highly effective in managing the disease when taken consistently. However, nonadherence is relatively common and can lead to reduced rates of response and increased medical costs. Similar effects of nonadherence on outcome and cost have also been observed in patients with various other hematologic malignancies and solid tumors. Interventions to improve adherence to oral chemotherapy regimens include communication about the importance of adherence and the potential consequences of nonadherence, simplification of the patient's medication schedule (if possible), and inclusion of a caregiver or family member in the conversation. Written materials should always be provided to accompany verbal instructions. This review summarizes factors influencing medication adherence, impact of nonadherence on patient outcomes, methods for measuring adherence, previous studies of nonadherence in patients with cancer, common barriers to access, and interventions to improve adherence in the community setting.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24877187     DOI: 10.1002/phar.1399

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  23 in total

1.  Interventions to Enhance Adherence to Oral Antineoplastic Agents: A Scoping Review.

Authors:  Shoshana M Rosenberg; Keith J Petrie; Annette L Stanton; Lan Ngo; Emma Finnerty; Ann H Partridge
Journal:  J Natl Cancer Inst       Date:  2020-05-01       Impact factor: 13.506

Review 2.  Oral Chemotherapy in Patients with Hematological Malignancies-Care Process, Pharmacoeconomic and Policy Implications.

Authors:  Jeffrey Betcher; Elizabeth Dow; Nandita Khera
Journal:  Curr Hematol Malig Rep       Date:  2016-08       Impact factor: 3.952

3.  The relationship between patient activation, confidence to self-manage side effects, and adherence to oral oncolytics: a pilot study with Michigan oncology practices.

Authors:  Teresa M Salgado; Emily Mackler; Jane A Severson; Jamie Lindsay; Peter Batra; Laura Petersen; Karen B Farris
Journal:  Support Care Cancer       Date:  2017-01-20       Impact factor: 3.603

4.  Cost-Related Medication Nonadherence and Patient Cost Responsibility for Rural and Urban Cancer Survivors.

Authors:  Courtney P Williams; Amy Davidoff; Michael T Halpern; Michelle Mollica; Kathleen Castro; Benjamin Allaire; Janet S de Moor
Journal:  JCO Oncol Pract       Date:  2022-08

5.  Adherence to Hormonal Therapy in Breast Cancer Patients in Saudi Arabia: A Single-Center Study.

Authors:  Attiah Khobrani; Yasser Alatawi; Eshtyag Bajnaid; Omima Alemam; Abubakr Osman; Lina Bin Attash; Mohammed Jaffal; Mohammed AlGhanmi; Adnan Alharbi; Mohammed Alnuhait
Journal:  Cureus       Date:  2022-05-06

6.  Enhancing patients' understanding of and adherence to oral anticancer medication: Results of a longitudinal pilot intervention.

Authors:  Mingqian Lin; Douglas Hackenyos; Nicole Savidge; Ruth Ann Weidner; Rachel Murphy-Banks; Tara Fleckner; Susan K Parsons; Angie Mae Rodday
Journal:  J Oncol Pharm Pract       Date:  2020-09-30       Impact factor: 1.809

7.  Are Australian clinicians monitoring medication adherence in hematological cancer survivors? Two cross-sectional studies.

Authors:  Marita C Lynagh; Tara Clinton-McHarg; Alix Hall; Rob Sanson-Fisher; William Stevenson; Campbell Tiley; Alessandra Bisquera
Journal:  Exp Hematol Oncol       Date:  2015-06-11

8.  Compliance with adjuvant capecitabine in patients with stage II and III colon cancer: comparison of administrative versus medical record data.

Authors:  Adam Amlani; Aalok Kumar; Jenny Y Ruan; Winson Y Cheung
Journal:  Cancer Med       Date:  2016-05-26       Impact factor: 4.452

9.  Oral Antineoplastic Agents: Assessing the Delay in Care.

Authors:  Brandi Anders; Alexandra Shillingburg; Michael Newton
Journal:  Chemother Res Pract       Date:  2015-10-28

Review 10.  Pharmacist-managed clinics for patient education and counseling in Japan: current status and future perspectives.

Authors:  Kiyofumi Yamada; Toshitaka Nabeshima
Journal:  J Pharm Health Care Sci       Date:  2015-01-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.